-
公开(公告)号：US10589001B2
公开(公告)日：2020-03-17
申请号：US13226618
申请日：2011-09-07
摘要： A pharmaceutical formulation for use in a spinal fusion method, comprising a composition for forming a matrix, a kit comprising the composition, a pharmaceutical product obtainable from the pharmaceutical formulation, and an interbody spinal fusion cage containing the pharmaceutical formulation or the pharmaceutical product are described herein. The composition comprises at least a first matrix material precursor component and a second matrix material precursor component that are able to crosslink to form the matrix under appropriate conditions, a bioactive factor that is biologically active for stimulating bone formation between two vertebrae and for effecting or supporting spinal fusion. The bioactive factor is PTH, optionally a PTH fusion peptide. The bioactive factor is releasably incorporated in the matrix upon crosslinking of the matrix material precursor components.
-
公开(公告)号：US20120234718A1
公开(公告)日：2012-09-20
申请号：US13226618
申请日：2011-09-07
CPC分类号： A61L27/12 , A61L27/225 , A61L27/227 , A61L27/46 , A61L27/54 , A61L2300/414 , A61L2300/43 , A61L2400/06 , A61L2430/38
摘要： A pharmaceutical formulation for use in a spinal fusion method, comprising a composition for forming a matrix, a kit comprising the composition, a pharmaceutical product obtainable from the pharmaceutical formulation, and an interbody spinal fusion cage containing the pharmaceutical formulation or the pharmaceutical product are described herein. The composition comprises at least a first matrix material precursor component and a second matrix material precursor component that are able to crosslink to form the matrix under appropriate conditions, a bioactive factor that is biologically active for stimulating bone formation between two vertebrae and for effecting or supporting spinal fusion. The bioactive factor is PTH, optionally a PTH fusion peptide. The bioactive factor is releasably incorporated in the matrix upon crosslinking of the matrix material precursor components.
摘要翻译： 描述了用于脊柱融合方法的药物制剂，其包含用于形成基质的组合物，包含所述组合物的试剂盒，可从药物制剂获得的药物产品和包含药物制剂或药物产品的体内脊椎融合器 这里。 所述组合物包含至少第一基质材料前体组分和第二基质材料前体组分，所述第一基质材料前体组分和第二基质材料前体组分能够在合适的条件下交联以形成基质;生物活性因子，其对于刺激两个椎骨之间的骨形成有生物活性，并用于实现或支持 脊柱融合 生物活性因子是PTH，任选地是PTH融合肽。 当基质材料前体组分交联时，生物活性因子可释放地并入基质中。
-
3.发明授权Medicament containing a tissue inhibitor of metalloproteinases-2 (TIMP-2) as an osteoanabolically active substance 失效含有金属蛋白酶-2（TIMP-2）的组织抑制剂作为骨代谢活性物质的药物公开(公告)号：US07232796B2
公开(公告)日：2007-06-19
申请号：US10239870
申请日：2001-04-04
CPC分类号： A61K38/57 , A61K38/1777
摘要： The invention relates to tissue inhibitor of metalloproteinase-2 (TIMP-2) as an osteoanabolically active peptide for use as a medicament for treating bone defects, bone diseases and for improving bone regeneration.
摘要翻译： 本发明涉及金属蛋白酶-2（TIMP-2）作为骨代谢活性肽的组织抑制剂，用作治疗骨缺损，骨疾病和改善骨再生的药物。
-
-
搜索结果
3 条记录 (耗时 0.054 秒)
